Discovery of quinacrine as a potent topo ii and hsp90 dual-target inhibitor, repurposing for cancer therapy

HIGHLIGHTS

• who: Xin Pan and collaborators from the School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China have published the article: Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy, in the Journal: Molecules 2022, 27, 5561. of 29/04/2022
• what: The study provides a hit compound QA that can target the ATP-binding domain of Topo II and Hsp90 with significant antiproliferation and remains sensitive to resistant cell lines.
• how: The study first shows that it has great potential as a dual-target . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.